228 related articles for article (PubMed ID: 37137901)
21. DNAJB1-PRKACA is specific for fibrolamellar carcinoma.
Graham RP; Jin L; Knutson DL; Kloft-Nelson SM; Greipp PT; Waldburger N; Roessler S; Longerich T; Roberts LR; Oliveira AM; Halling KC; Schirmacher P; Torbenson MS
Mod Pathol; 2015 Jun; 28(6):822-9. PubMed ID: 25698061
[TBL] [Abstract][Full Text] [Related]
22. Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion.
Graham RP; Lackner C; Terracciano L; González-Cantú Y; Maleszewski JJ; Greipp PT; Simon SM; Torbenson MS
Hepatology; 2018 Oct; 68(4):1441-1447. PubMed ID: 29222914
[TBL] [Abstract][Full Text] [Related]
23. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.
Bauer J; Köhler N; Maringer Y; Bucher P; Bilich T; Zwick M; Dicks S; Nelde A; Dubbelaar M; Scheid J; Wacker M; Heitmann JS; Schroeder S; Rieth J; Denk M; Richter M; Klein R; Bonzheim I; Luibrand J; Holzer U; Ebinger M; Brecht IB; Bitzer M; Boerries M; Feucht J; Salih HR; Rammensee HG; Hailfinger S; Walz JS
Nat Commun; 2022 Oct; 13(1):6401. PubMed ID: 36302754
[TBL] [Abstract][Full Text] [Related]
24. A genomic case study of mixed fibrolamellar hepatocellular carcinoma.
Griffith OL; Griffith M; Krysiak K; Magrini V; Ramu A; Skidmore ZL; Kunisaki J; Austin R; McGrath S; Zhang J; Demeter R; Graves T; Eldred JM; Walker J; Larson DE; Maher CA; Lin Y; Chapman W; Mahadevan A; Miksad R; Nasser I; Hanto DW; Mardis ER
Ann Oncol; 2016 Jun; 27(6):1148-1154. PubMed ID: 27029710
[TBL] [Abstract][Full Text] [Related]
25. β-catenin cancer-enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma.
Gulati R; Johnston M; Rivas M; Cast A; Kumbaji M; Hanlon MA; Lee S; Zhou P; Lake C; Schepers E; Min KW; Yoon JH; Karns R; Reid LM; Lopez-Terrada D; Timchenko L; Parameswaran S; Weirauch MT; Ranganathan S; Bondoc A; Geller J; Tiao G; Shin S; Timchenko N
Hepatol Commun; 2022 Oct; 6(10):2950-2963. PubMed ID: 36000549
[TBL] [Abstract][Full Text] [Related]
26. Intracranial metastasis in fibrolamellar hepatocellular carcinoma.
Hammond WJ; Lalazar G; Saltsman JA; Farber BA; Danzer E; Sherpa TC; Banda CD; Andolina JR; Karimi S; Brennan CW; Torbenson MS; La Quaglia MP; Simon SM
Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286561
[TBL] [Abstract][Full Text] [Related]
27. Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms.
Lalazar G; Simon SM
Semin Liver Dis; 2018 Feb; 38(1):51-59. PubMed ID: 29471565
[TBL] [Abstract][Full Text] [Related]
28. Human liver organoids for disease modeling of fibrolamellar carcinoma.
Narayan NJC; Requena D; Lalazar G; Ramos-Espiritu L; Ng D; Levin S; Shebl B; Wang R; Hammond WJ; Saltsman JA; Gehart H; Torbenson MS; Clevers H; LaQuaglia MP; Simon SM
Stem Cell Reports; 2022 Aug; 17(8):1874-1888. PubMed ID: 35803261
[TBL] [Abstract][Full Text] [Related]
29. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.
Honeyman JN; Simon EP; Robine N; Chiaroni-Clarke R; Darcy DG; Lim II; Gleason CE; Murphy JM; Rosenberg BR; Teegan L; Takacs CN; Botero S; Belote R; Germer S; Emde AK; Vacic V; Bhanot U; LaQuaglia MP; Simon SM
Science; 2014 Feb; 343(6174):1010-4. PubMed ID: 24578576
[TBL] [Abstract][Full Text] [Related]
30. Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.
Abou-Alfa GK; Mayer R; Venook AP; O'Neill AF; Beg MS; LaQuaglia M; Kingham PT; Kobos R; Basturk O; Brennan C; Yopp A; Harding JJ; Leong S; Crown J; Hoti E; Leonard G; Ly M; Bradley M; Valentino E; Markowitz D; Zukiwski A; Ren K; Gordan JD
Oncologist; 2020 Dec; 25(12):e1837-e1845. PubMed ID: 32154962
[TBL] [Abstract][Full Text] [Related]
31. Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report.
Kang S; Magliocca J; Sellers M; Roccaro G; Zheng W; Pectasides M; Draper A; Guadagno J; El-Rayes B; Akce M
Oncol Res Treat; 2022; 45(7-8):430-437. PubMed ID: 35537414
[TBL] [Abstract][Full Text] [Related]
32. Conformational Landscape of the PRKACA-DNAJB1 Chimeric Kinase, the Driver for Fibrolamellar Hepatocellular Carcinoma.
Tomasini MD; Wang Y; Karamafrooz A; Li G; Beuming T; Gao J; Taylor SS; Veglia G; Simon SM
Sci Rep; 2018 Jan; 8(1):720. PubMed ID: 29335433
[TBL] [Abstract][Full Text] [Related]
33. Integrated Phosphoproteomics for Identifying Substrates of Human Protein Kinase A (
Karamafrooz A; Brennan J; Thomas DD; Parker LL
J Proteome Res; 2021 Oct; 20(10):4815-4830. PubMed ID: 34436901
[TBL] [Abstract][Full Text] [Related]
34. Nuclear BAP1 loss is common in intrahepatic cholangiocarcinoma and a subtype of hepatocellular carcinoma but rare in pancreatic ductal adenocarcinoma.
Mosbeh A; Halfawy K; Abdel-Mageed WS; Sweed D; Rahman MHA
Cancer Genet; 2018 Aug; 224-225():21-28. PubMed ID: 29778232
[TBL] [Abstract][Full Text] [Related]
35. Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma.
Riggle KM; Turnham R; Scott JD; Yeung RS; Riehle KJ
Pediatr Blood Cancer; 2016 Jul; 63(7):1163-7. PubMed ID: 26990031
[TBL] [Abstract][Full Text] [Related]
36. Generation of combined hepatocellular-cholangiocarcinoma through transdifferentiation and dedifferentiation in p53-knockout mice.
Liu Y; Xin B; Yamamoto M; Goto M; Ooshio T; Kamikokura Y; Tanaka H; Meng L; Okada Y; Mizukami Y; Nishikawa Y
Cancer Sci; 2021 Aug; 112(8):3111-3124. PubMed ID: 34051011
[TBL] [Abstract][Full Text] [Related]
37. Enhanced cAMP-stimulated protein kinase A activity in human fibrolamellar hepatocellular carcinoma.
Riggle KM; Riehle KJ; Kenerson HL; Turnham R; Homma MK; Kazami M; Samelson B; Bauer R; McKnight GS; Scott JD; Yeung RS
Pediatr Res; 2016 Jul; 80(1):110-8. PubMed ID: 27027723
[TBL] [Abstract][Full Text] [Related]
38. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.
Kapur P; Peña-Llopis S; Christie A; Zhrebker L; Pavía-Jiménez A; Rathmell WK; Xie XJ; Brugarolas J
Lancet Oncol; 2013 Feb; 14(2):159-167. PubMed ID: 23333114
[TBL] [Abstract][Full Text] [Related]
39. Commentary on "Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation." Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX. Lancet Oncol 2013; 14(2):159-67. [Epub 2013 Jan 16]. doi: 10.1016/S1470-2045(12)70584-3.
Boorjian S
Urol Oncol; 2014 Aug; 32(6):934-5. PubMed ID: 25087671
[TBL] [Abstract][Full Text] [Related]
40. Tissue-specific significance of BAP1 gene mutation in prognostic prediction and molecular taxonomy among different types of cancer.
Wang XY; Wang Z; Huang JB; Ren XD; Ye D; Zhu WW; Qin LX
Tumour Biol; 2017 Jun; 39(6):1010428317699111. PubMed ID: 28618948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
